Back to Treatments

Treatment

Loteprednol etabonate ophthalmic suspension (short-term)

1
Conditions
60
Trials
9,000
Participants
65%
Average Safety

Condition Evidence

Dry Eye Disease

60 trials · 9,000 participants

75% effectiveness · 65% safety
Loteprednol etabonate ophthalmic suspension (short-term) | DFDA